A Phase 1/2 Single-Arm Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of MT-125 Monotherapy With Radiation in Newly Diagnosed Glioblastoma
This study is testing a new medication called MT-125 alongside standard radiation therapy for people newly diagnosed with glioblastoma, a type of aggressive brain cancer. The goal is to see if this new treatment is safe and if it helps radiation work better at destroying cancer cells.
This study is for adults 18 or older with a specific, newly diagnosed type of glioblastoma. You must also be generally healthy enough to carry out daily activities and meet specific blood count requirements set by the study doctors.
You will receive the new medication MT-125 on the same day as your radiation treatments. Since this is an early-stage study, researchers will carefully monitor you to find the best dose and to see how your body responds to the treatment.
The study is currently recruiting participants and is taking place at medical centers in Phoenix, Arizona; Jacksonville, Florida; and Rochester, Minnesota. Please check with your doctor to see if one of these locations is an option for you.
- 1This is the first time MT-125 is being tested in humans, so its effectiveness is not yet known.
- 2The treatment is designed to act directly on brain cancer cells to help radiation therapy work more effectively.
- 3Participation is voluntary, and your study doctor will discuss other options with you if you do not meet the specific requirements for this trial.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.